Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This meta-analysis found that laser-based therapies showed promising clinical benefits in treating scarring alopecias, such as disease stabilization and symptom improvement, but highlighted the need for high-quality randomized controlled trials due to serious risk of bias and methodological limitations in existing studies.

This case study reports that a 49-year-old female with scarring alopecia from chronic Discoid Lupus Erythematosus experienced hair regrowth and symptom relief with homeopathic treatment, although further clinical research is needed to confirm these effects.

In this study, among 450 patients treated with immune checkpoint inhibitors for metastatic melanoma, 1.33% developed scarring alopecia, all being female, with alopecia not impacting their cancer treatment continuation and a favorable cancer outcome reported.

In this case series, researchers reported scarring alopecia in six out of 450 patients (1.33%) treated with immune checkpoint inhibitors for metastatic melanoma, with all affected patients experiencing other immune-related adverse effects but continuing treatment with favorable cancer outcomes.

In this study, researchers reported a 1.33% prevalence of scarring alopecia among 450 patients treated with immune checkpoint inhibitors for metastatic melanoma, noting that hair loss did not require treatment discontinuation and seemed to coincide with favorable cancer outcomes.

Early diagnosis and tailored treatment are crucial to prevent permanent hair loss and support self-esteem in children with scarring alopecia.

This study examined alopecia coding trends using the American Academy of Dermatology's DataDerm registry, aiming to assess the impact of evaluation and management CPT coding updates pre- and post-2021 on reimbursement and visit complexity. Results were not reported in the abstract.

In a case reported by Dr. Batra’s Clinic, homeopathic treatment significantly improved scarring alopecia, addressing both physical and emotional symptoms and leading to overall recovery.

This case report highlights that scarring alopecia with features of dystrophic epidermolysis bullosa and lichen planopilaris can occur in patients with a COL7A1 mutation, emphasizing the need to recognize concurrent inflammatory causes.

This study suggests potential bidirectional causal links between certain sleep traits, like insomnia and reduced sleep duration, and types of alopecia, including alopecia areata; however, these associations did not hold after correcting for multiple tests, warranting cautious interpretation.

Hair loss negatively impacts quality of life, and psychological support can help.

In this case study, a patient with pseudopelades of Brocq was treated with a peripheral vasodilator, B vitamins, and corticosteroid lotion, leading to halted hair loss and improved clinical symptoms over seven weeks.

A machine learning model can predict scarring in lichen planopilaris using factors like vitamin D levels and diagnostic delay.

In this study, researchers found no significant differences in serum levels of ferritin, folate, vitamin B12, vitamin D, or thyroid function between patients with scarring alopecia and healthy controls, suggesting these factors may not play a major role in the disease's pathogenesis.

This study highlights significant psychosocial distress and access barriers faced by South Asian patients, suggesting improved provider education, broader insurance coverage, and enhanced patient assistance programs as necessary steps to achieve equitable healthcare access.

Scarring alopecia involves increased immune cells and specific gene changes near damaged hair follicles.

Low-dose isotretinoin is effective for treating pediatric scarring alopecia.

In this study, aged mice showed better regenerative skin outcomes than young mice, linked to a specific fibroblast subpopulation and enhanced signaling interactions that promote regeneration. EREG treatment improved young mice's skin regeneration, suggesting potential for scarless therapies.

In this retrospective chart review, researchers found that patients with scarring alopecia, including central centrifugal cicatricial alopecia, have a higher prevalence of various systemic comorbidities, such as vitamin D deficiency and metabolic syndrome, compared to the general US population.

This study observed that in a survey of individuals with scarring alopecia, those using chemical treatments or high-tension hairstyles experienced hair loss and alopecia diagnosis at a younger age, while hair dye use was linked to older age at hair loss onset and diagnosis.

In this cross-sectional study, both follicular lichen planus and discoid lupus erythematosus were identified as common causes of scarring alopecia, affecting young people with a more favorable prognosis for hair regrowth in discoid lupus erythematosus compared to follicular lichen planus.

CD8+ T cells attack hair follicle stem cells, causing scarring and hair loss in Discoid Lupus.

In this case report, a 74-year-old woman initially diagnosed with androgenetic alopecia was later found to have secondary alopecia neoplastica due to morpheaform basal cell carcinoma of the scalp, illustrating the importance of recognizing subtle clinical features to prevent delayed treatment and potential local destruction.

This study found that stem cell therapy before follicular unit extraction may improve hair restoration outcomes on scarred scalp tissue.

This study highlights a lack of research on the use of topical and low-dose oral minoxidil for treating scarring alopecia, despite their widespread application in other hair loss conditions.

This article reviews the clinical features, pathogenesis, and treatment strategies for Central Centrifugal Cicatricial Alopecia, emphasizing the need for enhanced understanding and early diagnosis, but reports no new research findings.

This study observed that adipose tissue infiltration and ESGC displacement in scalp biopsies were more frequently found in frontal fibrosing alopecia and may play a role in the development of scarring alopecia.

This summary from the EADV Congress, chaired by Ulrike Blume-Peytavi and Sergio Vaño-Galván, provided an overview of diagnosing and treating alopecia, but specific results and conclusions from the session were not reported in the abstract.

This study found that in mice, hyper-activated JAK-STAT1 signaling due to EGFR inhibitor treatment leads to scarring alopecia, but JAK1/2 inhibition can restore hair follicle immune privilege and promote new hair growth.

This study reviewed existing literature and found that androgenic alopecia may be associated with cardiovascular risk factors, while evidence for alopecia areata and cicatricial alopecias is limited and sometimes contradictory.